Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS643762 in stable schizophrenia
NCT01952132Phase 2Completed
- Sponsor
- Omeros Corporation
- Start
- Sep 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OMS824 in schizophrenia, sponsored by Omeros Corporation. Started Sep 2013; status: completed.
02
Drugs
OMS824
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01952132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952132.